Table 1.
Demographics and baseline characteristics of patients who switched to IND/GLY (ITT population)
| Characteristics | LABA + ICS n = 269 | IND/GLY n = 811 | LABA or LAMAb n = 268 | IND/GLYb n = 811 |
|---|---|---|---|---|
| Age, years | 64.4 (8.9) | 64.6 (8.7) | 65.2 (7.6) | 65.4 (8.3) |
| Gender – male, n (%) | 164 (61.0%) | 528 (65.1%) | 176 (65.7%) | 537 (66.2%) |
| Current smoker, n (%) | 138 (51.3%) | 392 (48.3%) | 135 (50.4%) | 435 (53.6%) |
| Post-bronchodilator FEV1, L | 1.76 (0.5) | 1.80 (0.5) | 1.76 (0.4) | 1.79 (0.5) |
| Post-bronchodilator FEV1, % predicted of normal value | 63.3 (8.3) | 63.7 (8.7) | 63.5 (8.2) | 63.8 (8.8) |
| Dyspnoea – mMRC grade, n (%) | ||||
| 0 | 1 (0.4%) | 11 (1.4%) | 2 (0.8%) | 2 (0.3%) |
| 1 | 138 (51.3%) | 435 (53.6%) | 28 (10.4%) | 63 (7.8%) |
| ≥ 2 | 129 (48.0%) | 365 (45.0%) | 238 (88.8%) | 745 (91.9%) |
| Number of exacerbation in the previous 12 months, n (%) | ||||
| 0 | 193 (71.8%) | 587 (72.4%) | 212 (79.1%) | 671 (82.7%) |
| 1 | 72 (26.8%) | 220 (27.1%) | 56 (20.9%) | 136 (16.8%) |
| ≥ 2 | 4 (1.5%) | 4 (0.5%) | 0 (0.0%) | 4 (0.5%) |
| Baseline treatments, n (%)a | ||||
| LAMA (only monotherapy) | - | 2 (0.2%) | 138 (51.3%) | 445 (55.1%) |
| LABA (only monotherapy) | - | 3 (0.4%) | 125 (46.5%) | 341 (42.2%) |
| LABA + ICS (free or fixed-dose combination) | 266 (98.9%) | 787 (96.7%) | - | 2 (0.3%) |
| Othersc | 12 (4.4%) | 39 (4.8%) | 12 (4.5%) | 44 (5.5%) |
aAt baseline, some of the patients were receiving more than one type of COPD medication
bPatients had an mMRC score ≥ 2
cICS, systemic corticosteroids, methylxanthines, roflumilast etc
Data are presented as mean (standard deviation), unless otherwise stated
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council